Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT), Tenet Healthcare (THC) and Upstream Bio, Inc. (UPB)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nuvectis Pharma (NVCT – Research Report), Tenet Healthcare (THC – Research Report) and Upstream Bio, Inc. (UPB – Research Report) with bullish sentiments.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nuvectis Pharma (NVCT)
In a report released today, Naz Rahman from Maxim Group reiterated a Buy rating on Nuvectis Pharma, with a price target of $17.00. The company’s shares closed last Thursday at $8.64.
According to TipRanks.com, Rahman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Nuvectis Pharma has an analyst consensus of Strong Buy, with a price target consensus of $15.67, representing a 73.3% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
Tenet Healthcare (THC)
In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on Tenet Healthcare. The company’s shares closed last Thursday at $229.04.
According to TipRanks.com, Macdonald is a 5-star analyst with an average return of
Tenet Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $250.00, implying a 29.6% upside from current levels. In a report issued on February 2, UBS also maintained a Buy rating on the stock with a $260.00 price target.
Upstream Bio, Inc. (UPB)
In a report released today, Danielle Brill from Truist Financial maintained a Buy rating on Upstream Bio, Inc.. The company’s shares closed last Thursday at $14.16.
According to TipRanks.com, Brill is a 5-star analyst with an average return of
Upstream Bio, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $48.80, implying an 86.8% upside from current levels. In a report issued on January 30, William Blair also maintained a Buy rating on the stock.
